Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.62 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18829255 | 1.00 | CYP3A4 (0.62) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL15033816 | 1.00 | CYP3A4 (0.62) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL22992301 | 1.00 | CYP3A4 (0.62) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL19558845 | 1.00 | CYP3A4 (0.62) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL19558843 | 0.99 | CYP3A4 (0.60) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL15023006 | 0.98 | CYP3A4 (0.59) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL21343837 | 0.98 | CYP3A4 (0.59) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL18829574 | 0.98 | CYP3A4 (0.59) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL15072195 | 0.95 | CYP3A4 (0.56) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL18829575 | 0.95 | CYP3A4 (0.56) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868745-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170342085-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
| US-9682989-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170145027-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20160115175-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2016-04-28 | — | — | US | disclosed |
| US-20150141326-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-05-21 | — | — | US | disclosed |
| US-8921341-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140112885-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20130177530-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145027-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | CYP3A4 2443/4885CYP2C9 3743/4885KCNH2 4579/4885 |
| US-20130177530-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | CYP3A4 2443/4885CYP2C9 3743/4885KCNH2 4579/4885 |
| US-20170342085-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | CYP3A4 2443/4885CYP2C9 3743/4885KCNH2 4579/4885 |
| US-20140112885-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | CYP3A4 2443/4885CYP2C9 3743/4885KCNH2 4579/4885 |
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | CYP3A4 2443/4885CYP2C9 3743/4885KCNH2 4579/4885 |
| US-20150141326-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | CYP3A4 2443/4885CYP2C9 3743/4885KCNH2 4579/4885 |
| US-20160115175-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | CYP3A4 2443/4885CYP2C9 3743/4885KCNH2 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.